# Phase 5 Full-Chain Verification

**Status:** complete mechanical/documentation verification for the Phase 5 gate.
**Remote CI:** Documentation Validation run 69 (`33615225543`) passed on commit `74040bd2ac7e8a6255d4eede80c0d5a4bec881b7`.

## 1. Measured chain inventory

| Layer | Measured |
|---|---:|
| Functional requirements | 60 |
| JTBD | 69 |
| Flows | 103 |
| Screens | 165 |
| Wireframes | 165 |
| Components | 22 |
| Interaction patterns | 26 |
| TXT families | 60 |
| Accessibility obligations | 40 |
| ERR families | 21 |
| Widgets | 30 |
| Implementation contracts | 30 |
| Manifest frames | 509 |

Platform screen baseline remains Patient 47, Clinic 56, Admin 62.

## 2. Manifest verification

Measured frame distribution:

- 01 · Tokens: 0 frame(s)
- 02 · Components: 137 frame(s)
- 03 · Widgets: 190 frame(s)
- 04 · Screens: 182 frame(s)

The manifest represents all 22 allocated CMP, all 30 WGT and all 165 SCR identifiers. It is light-mode-only for V1 and uses the Phase 3 token source. Flow membership is traceability metadata on screen frames rather than a separate FLOW frame identity.

## 3. Referential integrity

The Phase 5 validator is strengthened to require:

- every required Phase 5 artifact at the canonical lowercase path;
- manifest coverage for every allocated CMP, WGT and documented SCR;
- every allocated WGT to have exactly one implementation contract;
- every implementation contract to use the 29-section schema exactly once;
- every implementation contract to resolve at least one canonical FR/NFR;
- build-order slots to form a total unique sequence derived from the allocated WGT set;
- target path status, runtime, Profile A realization and component references to resolve mechanically;
- verification tiers A/B/C to exist in order;
- no unverified Patient package command to be presented as existing.

Earlier Phase 1–4 gates remain active and are not weakened.

## 4. Orphan review

Expected/required final result after the completion commit:

- orphan SCR: 0;
- orphan WF: 0;
- orphan CMP: 0;
- orphan IX: 0;
- orphan TXT: 0;
- orphan A11Y: 0;
- orphan WGT: 0;
- orphan implementation contract: 0;
- tracked uppercase `Docs/ux/` paths: 0.

`DESIGN_TRACEABILITY.md` carries the forward/reverse FR-to-build join.

## 5. Product-boundary regression review

The handoff preserves these non-negotiables:

- Patient discovery uses understandable service families and factual provider-option attributes.
- Internal S/P/H/I, calibration and service-risk machinery does not become Patient UI.
- PENDING_EVALUATION is not NOT_ELIGIBLE.
- FAILED_RETRYABLE evidence transfer is not authoritative REJECTED evidence.
- UPLOADED is not ACCEPTED.
- A pending booking alternative does not replace the confirmed appointment before accepted/revalidated commit.
- Accepted treatment and financial snapshots are immutable/history-preserving.
- Eligibility suspension has no UI override.
- Guardian/representation revocation remains reachable regardless of booking/case state.
- V1 has zero platform money movement; financial records describe external events.
- V1 is light-only across Patient, Clinic and Admin; the dark semantic map is future compatibility only.
- No optimistic rendering of clinical, financial or authorization outcomes.

## 6. Engineering prerequisites surfaced by translation

1. **Stage transition persistence.** Canonical state/cross-platform docs require append-only completion/reopening history. The current ERD `case_treatment_stages` shape stores current state and completion/reopen timestamps but does not by itself model repeated transition history. The implementation owner must resolve that persistence representation before stage mutation code.
2. **Draft persistence.** No generic drafts table is required. Treatment plan authoring uses `treatment_plan_versions` in DRAFT state; other domain drafts use their owning aggregate/version model where canonical.
3. **Durable in-system attention entries.** `TASK-PLATFORM-013` explicitly owns the durable patient notification-entry model/read path. `notification_intents` remain provider-neutral delivery intents and do not replace the durable attention read model.
4. **Patient repository.** The React Native repository/path and verified commands remain unverified under `TASK-PLATFORM-008`; all Patient target paths remain Proposed/path-unverified.

None of these changes UX semantics. Items 1, 3 and 4 are implementation/data prerequisites.

## 7. Open dependencies

Seven open Q items remain carried, not closed:

- `Q-PLATFORM-001` — complete readable-SRS reconciliation claim;
- `Q-PLATFORM-002` — final legal retention/deletion values;
- `Q-PLATFORM-004` — production capacity/headroom detail;
- `Q-PLATFORM-008` — final brand palette ratification;
- `Q-CATALOG-001` — licensed clinical catalog/content approval;
- `Q-ELIG-001` — licensed clinical formula/threshold approval;
- `Q-OPS-001` — concrete provider/infrastructure selection.

These are classified release/authority dependencies, not reasons for Phase 5 to fabricate values.

## 8. Verification tiers

### Tier A — documentation/mechanical

The promoted Phase 5 CI gate ran successfully on run 69:

- engineering validator: 0 failures / 0 warnings;
- UX `--phase 5`: 0 failures / 0 warnings;
- token validator: 935 tokens, 114/114 required light pairs and 114/114 dark-compatibility pairs, 0 failures;
- emoji gates: repository and docs clean;
- component token regeneration: 22 groups / 199 concrete tokens / 8 tone-bound groups, with zero generated diff.

### Tier B — rendered design QA

Deferred. BUILD_MANIFEST is machine-readable build input, not proof of a rendered design. A Claude/design-agent or human render review must verify visual hierarchy, rendered contrast, Arabic glyph behavior, responsive composition and state differentiation.

### Tier C — runtime QA

Deferred until implementation. VoiceOver/TalkBack Arabic output, keyboard/focus behavior, target sizes, browser/native reflow, reduced-motion behavior, server permission enforcement and real transition announcements cannot be proven by documentation.

No Tier B/C item is reported as passed here.

## 9. Case/path hygiene

Canonical UX path is `docs/ux/`; tracked uppercase `Docs/ux/` count is 0. No production source change is part of this Phase 5 completion run.

## 10. Final-gate result

The promoted remote workflow executed UX Phase 5 validation and every configured documentation/UX gate passed on run 69. The Phase 1–5 documentation/specification chain is therefore complete. Rendered design QA and runtime QA remain mandatory later evidence and are not included in this completion claim.
